Lazard Asset Management
KDNY

Lazard Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Lazard Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,700
Closed -$76K – 2628
2022
Q1 		$76K Buy
+4,700
New +$63.9K ﹤0.01% 1528
2020
Q3 		– Sell
-2,894
Closed -$33K – 1777
2020
Q2 		$33K Buy
+2,894
New +$39.9K ﹤0.01% 1338

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lazard Asset Management's KDNY Position: Q2 2022 in Review

Lazard Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2022, closing a stake of 4,700 shares — an estimated $76K sold.

Lazard Asset Management first reported a position in KDNY in Q2 2020 and held it in 2 quarters. The position peaked at $76K in Q1 2022. 135 funds tracked by Wall St. Rank hold KDNY as of Q2 2022.

  • Lazard Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Lazard Asset Management sold 4,700 Chinook Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $76K.
  • Lazard Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Lazard Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $76K in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Lazard Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.